World Allergy Organization Journal最新文献

{"title":"Penicillin allergy delabeling has a significant impact on subsequent antibiotic use in primary care","authors":"Sara Fransson MD, PhD ,&nbsp;Jonas B. Boel Msc.Pharm, PhD ,&nbsp;Holger F. Mosbech MD, DMSc ,&nbsp;Lene H. Garvey MD, PhD (Professor)","doi":"10.1016/j.waojou.2024.100958","DOIUrl":"10.1016/j.waojou.2024.100958","url":null,"abstract":"<div><p>Efforts to delabel penicillin allergic patients are important as the majority of suspected penicillin allergy can be ruled out by relevant allergy testing. The aim is to change the antibiotic pattern in delabeled patients to minimize use of unnecessary broad-spectrum antibiotics, reducing the risk of antimicrobial resistance and making treatment more cost effective. However, published information on subsequent antibiotic use is scarce.</p><p>To evaluate the effect of delabeling on subsequent antibiotic use in primary care, a cohort of 2911 patients tested for penicillin allergy was compared to a matched control group of 14,522 individuals from the background population. In total 86.4% of the tested patients were delabeled.</p><p>For delabeled patients, penicillin use increased from 0.07 prescriptions per patient year before allergy investigation, to 0.53 prescriptions per patient year post investigation (p &lt; 0.001). The use of fluoroquinolones and macrolides was reduced and reached a level comparable to the background population.</p><p>This study shows that penicillin allergy delabeling has significant positive impact on subsequent antibiotic use in primary care, and that penicillin use increases to levels similar to the background population. Penicillin allergy delabeling should be prioritized as an important and efficient element in antimicrobial stewardship initiatives.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100958"},"PeriodicalIF":3.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000899/pdfft?md5=293b4c8b62e7adab33415bdde61f37d6&pid=1-s2.0-S1939455124000899-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142039907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 antibody improves airway inflammation in mice with house dust mite induced asthma","authors":"Sung-Ryeol Kim MD ,&nbsp;Yun Jung Um MSc ,&nbsp;Sook In Chung PhD ,&nbsp;Kyoung Yong Jeong PhD ,&nbsp;Hye Jung Park MD ,&nbsp;Kyung Hee Park MD ,&nbsp;Jung-Won Park MD ,&nbsp;Sang Gyu Park PhD ,&nbsp;Jae-Hyun Lee MD","doi":"10.1016/j.waojou.2024.100956","DOIUrl":"10.1016/j.waojou.2024.100956","url":null,"abstract":"<div><h3>Background</h3><p>Several biologics have been developed and used to treat severe asthma. However, commercialized biologics have limitations in treating T2-low asthma because their main target is the T2 inflammation marker. Therefore, there is an unmet need for treating T2-low severe asthma. Aminoacyl-tRNA synthetase-interacting multifunctional protein 1 (AIMP1) is an auxiliary protein in the mammalian multi-aminoacyl-tRNA synthetase complex. AIMP1 also acts as a cytokine and induces the secretion of proinflammatory cytokines. Since anti-AIMP1 has been shown to reduce interleukin (IL)-6, tumor necrosis factor-α, and IL-17A levels in a mouse model, it could be effective in the treatment of T2-low severe asthma.</p></div><div><h3>Methods</h3><p>Wild-type BALB/c mice were sensitized and challenged with intranasal inoculation of a crude HDM extract. Atliximab, a chimeric AIMP1 antibody, was administered once (20 μg, 40 μg, 100 μg) on Day 14. We evaluated airway hyperresponsiveness (AHR), performed cellular analyses of the bronchoalveolar lavage fluid (BALF), measured inflammatory cytokine levels, and examined peribronchial histological features.</p></div><div><h3>Results</h3><p>Atliximab reduced AIMP1 levels in asthmatic mice in a dose-dependent manner. AHR and Inflammatory cells such as neutrophils and eosinophils in the BALF decreased in asthmatic mice treated with atliximab. The levels of IL-6, IL-13, and transforming growth factor-β (TGF-β) in the lung tissue decreased in asthmatic mice treated with a high dose of atliximab (100 μg). Atliximab also reduced goblet cell hyperplasia and peribronchial fibrosis.</p></div><div><h3>Conclusions</h3><p>Atliximab improved asthmatic airway inflammation including neutrophilic inflammation in HDM-induced asthma mice. These data suggest that anti-AIMP1 plays an important role in the treatment of severe T2-low asthma.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100956"},"PeriodicalIF":3.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000875/pdfft?md5=5fa5b67e8d7d1a6a02fec0a4a94bd3e2&pid=1-s2.0-S1939455124000875-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142044373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Galectin-10: A biomarker for persistent airflow limitation in adult asthmatics","authors":"Thi Bich Tra Cao, MD, PhD ,&nbsp;Quang Luu Quoc, MD, PhD ,&nbsp;Jae-Hyuk Jang, MD ,&nbsp;Eun-Mi Yang, MS ,&nbsp;Min Sook Ryu, PhD ,&nbsp;Youngwoo Choi, PhD ,&nbsp;Hae-Sim Park, MD, PhD","doi":"10.1016/j.waojou.2024.100955","DOIUrl":"10.1016/j.waojou.2024.100955","url":null,"abstract":"<div><h3>Background</h3><p>Inhaled corticosteroids (ICS) are primary anti-inflammatory medications to control eosinophilic airway inflammation, and prevent asthma exacerbation. However, persistent airflow limitation (PAL) presents in some asthmatics even on ICS treatment, leading to lung function decline. Thus, we evaluated clinical associations of serum galectin-10 (Gal10) and galectin-3 (Gal3) levels in adult asthmatics who had maintained anti-asthma medication.</p></div><div><h3>Methods</h3><p>Sixty-seven asthmatics and 78 healthy controls (HCs) were recruited. Serum Gal10 and Gal3 levels were measured by enzyme-linked immunosorbent assay, and their clinical relevance with inflammatory and lung function parameters was evaluated. Spirometry was performed to assess PAL and small airway dysfunction (SAD). Airway epithelial cells were cocultured with eosinophils/neutrophils, and were exposed to house dust mites to assess the production of Gal10 and Gal3.</p></div><div><h3>Results</h3><p>Serum Gal10 (not Gal3) levels were significantly higher in asthmatics than in HCs (<em>P</em> &lt; 0.001), in asthmatics with PAL than in those without PAL (<em>P</em> = 0.005), and in those with SAD than in those without SAD (<em>P</em> = 0.004). The Gal10-high group had significantly higher levels of peripheral CD66⁺ neutrophil counts, serum periostin and Gal3, and lower values of FEV₁% and MMEF% than the Gal10-low group (<em>P</em> &lt; 0.050 for all). The production of Gal10 and Gal3 was increased in eosinophilic airway model, while Gal10 (not Gal3) levels were increased in neutrophilic airway model as well as house dust mite stimulation.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that serum Gal10 level may be a potential biomarker for PAL in adult asthmatics.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100955"},"PeriodicalIF":3.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000863/pdfft?md5=46349697a194971f45bfc92c4c607f09&pid=1-s2.0-S1939455124000863-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twenty-five years: The fexofenadine clinical experience","authors":"Robert M. Naclerio MD ,&nbsp;Ignacio J. Ansotegui MD, PhD ,&nbsp;Giorgio Walter Canonica MD ,&nbsp;Philip Rouadi MD ,&nbsp;Luo Zhang MD ,&nbsp;Margarita Murrieta-Aguttes MD","doi":"10.1016/j.waojou.2024.100950","DOIUrl":"10.1016/j.waojou.2024.100950","url":null,"abstract":"<div><p>Allergic rhinitis (AR) and urticaria affect a sizable portion of the population worldwide, resulting in reduced quality-of-life and productivity and increased healthcare costs.</p><p>Fexofenadine (FEX) is a non-sedating second-generation H₁ antihistamine with pronounced efficacy and a very good safety profile, used for the treatment of allergic diseases. In addition to its antihistaminic properties, FEX also has anti-inflammatory effects. FEX has a wide therapeutic window and is not associated with any sedative effects, even at higher than recommended doses.</p><p>There is a need for an integrated management system for AR and urticaria which includes safe and effective treatment options.</p><p>An ideal anti-allergic formulation should provide fast relief of symptoms and long-lasting effect without drowsiness. Data from randomized clinical trials show that FEX meets these criteria and is an effective treatment option with a favourable safety profile, improving the quality of life of patients suffering from AR and urticaria.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100950"},"PeriodicalIF":3.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000814/pdfft?md5=d0f1209e11de86cb11795e4af2081d21&pid=1-s2.0-S1939455124000814-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug provocation tests (DPTs) of contrast media: Useful or not useful? – A narrative review","authors":"Manuel Dettwiler MMed ,&nbsp;Ingrid B. Boehm MD","doi":"10.1016/j.waojou.2024.100946","DOIUrl":"10.1016/j.waojou.2024.100946","url":null,"abstract":"<div><p>Drug provocation tests (DPTs) are also used in some patients with a history of a contrast medium (CM)-hypersensitivity reaction. Since the use of contrast agents requires special knowledge that is present in radiology but not necessarily in allergology, this overview should close the knowledge gaps. The literature, and the package inserts of the industry dealing with DPTs in contrast hypersensitivity reactions was analyzed and the results presented. Historical analyses revealed that provocation tests were already done in the past, and called pre-testing. Due to disadvantages, this diagnostic tool was abandoned. A few years later, DPT was introduced as an innovative diagnostic procedure. The DPT has the 3 main disadvantages: a missing standardization, patients at risk (such as compromised renal function) are rarely taken into account, and a negative DPT does not exclude a subsequent CM reaction. DPTs (formerly called pre-testing) are a well-known method for diagnosing CM-related hypersensitivity reactions. Since the disadvantages of this diagnosis outweigh the advantages, we propose replacing DPT with routine contrast-enhanced imaging examination in radiology.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100946"},"PeriodicalIF":3.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000772/pdfft?md5=dcfaceeedb9d86d93984989aac11943a&pid=1-s2.0-S1939455124000772-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic and hypersensitivity condition in the International Patients’ Summary (IPS) standard: The need of updates through the International Classification of Diseases (ICD)-11","authors":"Luciana Kase Tanno MD PhD, Alain Perie PhD, Jonathan A. Bernstein MD, James L. Sublett MD, Karapet Davtyan MD MPH MBA, Frederic Berard MD PhD, Ruby Pawankar MD PhD, Marylin Valentin Rostan MD, Herberto Chong MD PhD, Anahi Yañez MD, Ignacio J. Ansontegui MD PhD, Motohiro Ebisawa MD PhD, Gary W.K. Wong MD PhD, Mario Morais-Almeida MD, Bryan Martin MD, Yann Briand PhD, Pascal Demoly MD PhD, the American Academy of Allergy Asthma & Immunology (AAAAI), the American College of Allergy Asthma and Immunology (ACAAI), the Asia Pacific Association of Allergy Asthma and Clinical Immunology (APAAACI), the French Allergy Society (SFA), the French WHO Collaborating Centre, the WHO Regional Office for Europe, the Latin American Society of Allergy and Immunology (SLAAI), the Montpellier WHO Collaborating Centre, the World Allergy Organization (WAO)","doi":"10.1016/j.waojou.2024.100921","DOIUrl":"https://doi.org/10.1016/j.waojou.2024.100921","url":null,"abstract":"In 2010, the United States Human and Health Services (US HHS) and the European Union's (EU) Directorate General for Communications Networks, Content and Technology signed a memorandum of understanding to stimulate cooperation surrounding health-related information communications technology. The key project that emerged from this agreement is the (IPS), intended to provide succinct clinically relevant patient summaries, which are generalizable and condition-independent, that can be readily used by all clinicians for the care of patients. Although allergies are included in the main information required by the IPS library and framework, it is misrepresented which leads to underdiagnosis or misdiagnosis of patients suffering from allergic and hypersensitivity conditions (A/H). The French and Montpellier World Health Organization (WHO) Collaborating Centres have provided arguments for supporting representation of A/H in the IPS. These are based on the relevance of the new classification of A/H in the WHO International Classification of Diseases 11th version (ICD-11), and the need for alignment of eHealth tools with harmonized health information. We first present the A/H in the IPS initiative with the mission of producing an international information system that can be used globally in electronic health records to standardize clinical diagnoses and facilitate communication between clinicians caring for patients with A/H diseases. It is believed this initiative will provide a strong voice for the allergy community and an effective process for improving the quality of health data that will optimize medical care for our patients worldwide.","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"91 1","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142177434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study","authors":"Hyo-In Rhyou MD, PhD ,&nbsp;Hyun-Kyoung Kim MPH ,&nbsp;Woo-Jung Song MD, PhD ,&nbsp;Sang Min Lee MD, PhD ,&nbsp;Sang-Ha Kim MD, PhD ,&nbsp;Jae-Woo Kwon MD, PhD ,&nbsp;Han-Ki Park MD, PhD ,&nbsp;Hye-Kyung Park MD, PhD ,&nbsp;Sang Hoon Kim MD, PhD ,&nbsp;Jeong-Hee Choi MD, PhD ,&nbsp;Sujeong Kim MD, PhD ,&nbsp;So-Young Park MD, PhD ,&nbsp;Sae-Hoon Kim MD, PhD ,&nbsp;Ji-Yong Moon MD, PhD ,&nbsp;Jae-Woo Jung MD, PhD ,&nbsp;Young-Joo Cho MD, PhD ,&nbsp;Chan Sun Park MD, PhD ,&nbsp;Byung Keun Kim MD, PhD ,&nbsp;Joo-Hee Kim MD, PhD ,&nbsp;Min-Suk Yang MD, PhD ,&nbsp;Tae-Bum Kim MD, PhD","doi":"10.1016/j.waojou.2024.100957","DOIUrl":"10.1016/j.waojou.2024.100957","url":null,"abstract":"<div><h3>Background</h3><p>Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and compare the efficacy of different T2-directed biologics using QoL questionnaires.</p></div><div><h3>Methods</h3><p>We compared the QoL between severe and mild-to-moderate asthma and between severe asthma with and without biologics treatment. Data of mild-to-moderate were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea, and data of severe asthma were collected from the Precision Medicine Intervention in Severe Asthma. We included 183 patients with severe asthma treated with T2 biologics or conventional therapy between April 2020 and May 2021 and assessed QoL of them using the Questionnaire for Adult Korean Asthmatics (QLQAKA), Severe Asthma Questionnaire (SAQ), and EuroQoL-5Dimensions (EQ-5D) at baseline and 6 months.</p></div><div><h3>Results</h3><p>The EQ-5D index (0.803) of severe asthma was lower than that of other chronic diseases representing a worse QoL. The scores for all questions of QLQAKA, except “cough,” were lower (less control) in the severe asthma group than in the mild-to-moderate asthma group at baseline and 6 months (<em>P</em> &lt; 0.05). The total scores and subscores of all domains of the QLQAKA, SAQ, and EQ-5D improved significantly 6 months after biologic therapy but not after conventional therapy. The total QLQAKA, SAQ, and EQ-5D scores improved after 6 months in the anti-IL-5 (<em>P</em> &lt; 0.05) and anti-IL-4/IL-13 (<em>P</em> &lt; 0.05) treatment groups with no significant difference between groups (<em>P</em> &gt; 0.05).</p></div><div><h3>Conclusion</h3><p>QoL was worse in severe asthma than in mild-to-moderate asthma and other chronic diseases. T2 biologics equally improved QoL in patients with severe asthma.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100957"},"PeriodicalIF":3.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000887/pdfft?md5=ff4eb96c06bff5c16bd0b552f1cd6e80&pid=1-s2.0-S1939455124000887-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of allergic rhinitis is undermanaged in a large proportion of Chinese young adults from Singapore","authors":"Qi Yi Ambrose Wong BSC (Hons),&nbsp;Jun Jie Lim BSc (Hons),&nbsp;Jun Yan Ng BSc (Hons),&nbsp;Praneeth Malipeddi MSc,&nbsp;Yi Ying Eliza Lim BSc (Hons),&nbsp;Yang Yie Sio Ph.D.,&nbsp;Fook Tim Chew Ph.D.","doi":"10.1016/j.waojou.2024.100954","DOIUrl":"10.1016/j.waojou.2024.100954","url":null,"abstract":"<div><h3>Background</h3><p>Allergic rhinitis (AR) is a nasal disorder characterized by the simultaneous manifestation of at least 2 out of 4 possible symptoms: rhinorrhea, nasal itching, nasal pruritus, and sneezing. Presently, among Chinese young adults from Singapore, we characterised AR phenotypes, established Total Nasal Symptom Score (TNSS) baselines, and examined the management of AR.</p></div><div><h3>Methods</h3><p>Participants completed an investigator-administered International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire and underwent a skin prick test (SPT). Individuals exhibiting sensitization during the SPT while having at least 2 rhinitis symptoms were identified as AR cases, then categorized into Allergic Rhinitis in Asthma (ARIA) classifications.</p></div><div><h3>Results</h3><p>There were 9323 subjects analyzed. AR prevalence was estimated at 35.4%. Rhinorrhea was perceived as the most severe (mean Nasal Symptom Score (mNSS) ± SD: 1.42 ± 0.74), while nasal pruritus was the least severe (mNSS ± SD: 1.24 ± 0.68). Among moderate-severe AR (68.1%), most were affected by either troublesome symptoms (27.7%) or sleep disturbances (18.4%). By ARIA classes, 26.6% were mild intermittent, 5.4% were mild persistent, 50.3% were moderate-severe intermittent, and 17.6% were moderate-severe persistent. The mean TNSS (mTNSS) of AR cases was 4.43 (SD = 2.49) and between AR classifications, the mTNSS was significantly different. Notably, a large proportion of AR cases remained undiagnosed (85.2%), untreated (72.5%), or both (65.4%); 19.8% self-medicated for AR.</p></div><div><h3>Conclusions</h3><p>There was a significant difference in TNSS of the AR phenotypes, and among phenotypes with a higher mTNSS, a large proportion remained untreated, undiagnosed, or both. The evidence indicates an existing burden of AR among Chinese young adults in Singapore which is notably undermanaged.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 9","pages":"Article 100954"},"PeriodicalIF":3.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000851/pdfft?md5=704eba7a94756e704aca6ff08ade6be3&pid=1-s2.0-S1939455124000851-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) – Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions","authors":"Fiona James BBiomedSci ,&nbsp;Michelle S. Goh MBBS ,&nbsp;Sara Vogrin MBiostat ,&nbsp;Irvin Ng PhD ,&nbsp;Abby P. Douglas PhD ,&nbsp;Natasha E. Holmes PhD ,&nbsp;Kyra YL. Chua PhD ,&nbsp;Joseph De Luca MBBS ,&nbsp;Pooja Sharma MD ,&nbsp;Celia Zubrinich MPhil ,&nbsp;Ar K. Aung MBBS ,&nbsp;Douglas Gin MBBS ,&nbsp;Belinda Lambros MAdvNursPrac ,&nbsp;Chris Baker MBBS ,&nbsp;Peter Foley MD ,&nbsp;Alvin H. Chong MMed ,&nbsp;Francis Thien MD ,&nbsp;Jie S. Fok MBBS ,&nbsp;John Su MBBS ,&nbsp;Laura Scardamaglia MBBS ,&nbsp;Jason A. Trubiano PhD","doi":"10.1016/j.waojou.2024.100936","DOIUrl":"10.1016/j.waojou.2024.100936","url":null,"abstract":"<div><h3>Background</h3><p>Severe cutaneous adverse reactions (SCAR) are a group of delayed presumed T-cell mediated hypersensitivities associated with significant morbidity and mortality. Despite their shared global healthcare burden and impact, the clinical phenotypes, genomic predisposition, drug causality, and treatment outcomes may vary. We describe the establishment and results from the first Australasian registry for SCAR (AUS-SCAR), that via a collaborative network advances strategies for the prevention, diagnosis and treatment of SCAR.</p></div><div><h3>Methods</h3><p>Prospective multi-center registry of SCAR in Australian adult and adolescents, with planned regional expansion. The registry collects externally verified phenotypic data drug causality, therapeutics and long-term patient outcomes. In addition, biorepository specimens and DNA are collected at participating sites.</p></div><div><h3>Results</h3><p>we report on the first 100 patients enrolled in the AUS-SCAR database. DRESS (50%) is the most predominant phenotype followed by SJS/TEN (39%) and AGEP (10%), with median age of 52 years old (IQR 37.5, 66) with 1:1 male-to-female ratio. The median latency for all implicated drugs is highly variable but similar for DRESS (median 15 days IQR 5,25) and SJS/TEN (median 21 days, IQR 7,27), while lowest for AGEP (median 2.5 days, IQR 1,8). Antibiotics (54.5%) are more commonly listed as primary implicated drug compare with non-antibiotics agent (45.5%). Mortality rate at 90 days was highest in SJS/TEN at 23.1%, followed by DRESS (4%) and AGEP (0%).</p></div><div><h3>Conclusion</h3><p>In the first prospective national phenotypic and biorepository of SCAR in the southern hemisphere we demonstrate notable differences to other reported registries; including DRESS-predominant phenotype, varied antibiotic causality and low overall mortality rate. This study also highlights the lack of standardised preventative pharmacogenomic measures and <em>in vitro</em>/<em>in vivo</em> diagnostic strategies to ascertain drug causality.</p></div><div><h3>Trial registration</h3><p>ANZCTR ACTRN12619000241134. Registered 19 February 2019.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 8","pages":"Article 100936"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S193945512400067X/pdfft?md5=0260a54465065321a2ef23b882d23af7&pid=1-s2.0-S193945512400067X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic analysis of cardiovascular disease-associated proteins in Korean patients with moderate-to-severe atopic dermatitis","authors":"Seon-Pil Jin MD, PhD ,&nbsp;Hosu Kim MD ,&nbsp;Ji Hwan Moon PhD ,&nbsp;Seunghee Kim-Schulze PhD ,&nbsp;Yookyung Sophie Chun BS ,&nbsp;Hyo Jeong Nam BS ,&nbsp;Yoon Ji Bang BS ,&nbsp;Ji Su Lee MD, PhD ,&nbsp;Jung Eun Kim MD, PhD ,&nbsp;Chung-Gyu Park MD, PhD ,&nbsp;Hyun Je Kim MD, PhD ,&nbsp;Dong Hun Lee MD, PhD","doi":"10.1016/j.waojou.2024.100949","DOIUrl":"10.1016/j.waojou.2024.100949","url":null,"abstract":"<div><h3>Background</h3><p>Cardiovascular diseases (CVDs) have been associated with atopic dermatitis (AD), including in Korean patients. Previous studies on AD have primarily focused on patients of European ancestry, while the Asian endotype exhibits distinct characteristics. This study aimed to characterize the blood proteomic signature of Korean patients with moderate-to-severe AD, with an emphasis on proteins related to CVDs.</p></div><div><h3>Methods</h3><p>A total of 78 participants, including 39 patients with moderate-to-severe AD and 39 age- and sex-matched healthy controls, were enrolled. Blood proteomics analysis was performed using the Olink CVD II panel, which measures the expression levels of 92 proteins associated with CVDs.</p></div><div><h3>Results</h3><p>Unsupervised hierarchical clustering revealed 44 upregulated and 5 downregulated proteins in AD patients compared to healthy controls. Principal component analysis (PCA) effectively distinguished AD patients from healthy subjects based on the complete set of proteins or the subset of upregulated proteins. A multiple linear regression model comprising CCL17 and FGF21 showed a strong correlation with disease severity (R = 0.619). Correlation analysis identified 25 highly correlated proteins, including STK4, ITGB1BP2, and DECR1, which were newly found to be upregulated in Korean AD patients. Pathway analysis highlighted the involvement of these proteins in vascular system, inflammation, and lipid metabolism pathways.</p></div><div><h3>Conclusion</h3><p>The blood proteomic profile of moderate-to-severe AD patients in Korea differed from healthy controls using the CVD II panel. This study provides potential biomarkers for the AD-CVD association and insights into the pathways contributing to this relationship in the Korean population.</p></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 8","pages":"Article 100949"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1939455124000802/pdfft?md5=b0ca8d5b954693f598553d79af6abf94&pid=1-s2.0-S1939455124000802-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141953153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}